THE SINGLE BEST STRATEGY TO USE FOR AGO TUMOR

Molecular typing is predicated on molecular genetic screening and isn't but routinely offered. Molecular subtypes and immunohistochemical surrogate markers in the tumors (HR, HER2, triple adverse) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 could possibly be useful, but a